

1 **A longitudinal study of SARS-CoV-2 infected patients shows high correlation**
2 **between neutralizing antibodies and COVID-19 severity**

3

4 **Authors**

5 Vincent Legros^{1,2,\$}, Solène Denolly^{1,\$}, Manon Vogrig^{3,4}, Bertrand Boson¹, Josselin Rigail^{3,4},
6 Sylvie Pillet^{3,5}, Florence Grattard^{3,5}, Sylvie Gonzalo³, Paul Verhoeven^{3,5}, Omran Allatif¹,
7 Philippe Berthelot^{5,6}, Carole Péliissier⁷, Guillaume Thierry⁸, Elisabeth Botelho-Nevers^{5,6},
8 Stéphane Paul^{4,5}, Thierry Walzer¹, François-Loïc Cosset^{1,*,**}, Thomas Bourlet^{3,5,**} and Bruno
9 Pozzetto^{3,5,**}

10

11 **Affiliations**

12 ¹CIRI – Centre International de Recherche en Infectiologie, Team EVIR, Univ Lyon, Université
13 Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, 46 allée d’Italie, F-
14 69007, Lyon, France.

15 ²Université de Lyon, VetAgro Sup, Marcy-l’Étoile, France.

16 ³Department of Infectious Agents and Hygiene, University-Hospital of Saint-Etienne, Saint-
17 Etienne, France

18 ⁴Department of Immunology, University-Hospital of Saint-Etienne, Saint-Etienne, France

19 ⁵CIRI – Centre International de Recherche en Infectiologie, Team GIMAP, Univ Lyon,
20 Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, 46 allée
21 d’Italie, F-69007, Lyon, France.

22 ⁶Department of Infectious Diseases, University-Hospital of Saint-Etienne, Saint-Etienne, France.

23 ⁷Department of Occupational Medicine, University-Hospital of Saint-Etienne, Saint-Etienne,
24 France.

25 ⁸Department of Intensive Care and Resuscitation (Réanimation G), University-Hospital of Saint-
26 Etienne, Saint-Etienne, France

27 [§]These two authors contributed equally to the completion of this study.

28 ^{**}These three authors contributed equally to the completion of this study.

29

30 *Corresponding author: e-mail: flcosset@ens-lyon.fr; tel: +33472728732

31

32 **Abstract**

33 Understanding the immune responses elicited by SARS-CoV-2 infection is critical in terms of
34 protection from re-infection and, thus, for public health policy and for vaccine development
35 against the COVID-19. Here, using either live SARS-CoV-2 particles or retroviruses
36 pseudotyped with the SARS-CoV-2 S viral surface protein (Spike), we studied the neutralizing
37 antibody (nAb) response in serum specimens from a cohort of 140 SARS-CoV-2 qPCR-
38 confirmed patients, including patient with mild symptoms but also more severe form including
39 those that require intensive care. We show that nAb titers were strongly correlated with disease
40 severity and with anti-Spike IgG levels. Indeed, patients from intensive care units exhibited high
41 nAb titers, whereas patients with milder disease symptoms displayed heterogenous nAb titers
42 and asymptomatic or exclusive outpatient care patients had no or poor nAb levels. We found that
43 the nAb activity in SARS-CoV-2-infected patients displayed a relatively rapid decline after
44 recovery, as compared to individuals infected with alternative coronaviruses. We show the
45 absence of cross-neutralization between endemic coronaviruses and SARS-CoV-2, indicating
46 that previous infection by human coronaviruses may not generate protective nAb against SARS-
47 CoV-2 infection. Finally, we found that the D614G mutation in the Spike protein, which has
48 recently been identified as the major variant now found in Europe, does not allow neutralization
49 escape. Altogether, our results contribute to the understanding of the immune correlate of SARS-
50 CoV-2 induced disease and claim for a rapid evaluation of the role of the humoral response in
51 the pathogenesis of SARS-CoV-2.

52

53 **Keywords**

54 Antibody; Pathogenesis; Humoral response; COVID-19; SARS; Virus

55

56 **Introduction**

57 Emergence of SARS-CoV-2 was first detected in late 2019 in Wuhan, China. As per John
58 Hopkins University and Coronavirus Resource Center, the SARS-CoV-2-induced disease, named
59 COVID-19, has now caused by mid-August 2020 more than 750,000 reported deaths worldwide
60 for over 21 million infected individuals, figures that are likely to be underestimated. The
61 hallmark of the disease is an acute respiratory distress syndrome (ARDS), but other non-specific
62 symptoms such as sore throat, dry cough, fever, fatigue, muscle aches, runny nose, and diarrhea
63 are also frequently present [1]. Neurologic disorders have also been reported with headache,
64 nausea, vomiting, anosmia and aguesia, acute cerebrovascular diseases, Guillain-Barré
65 syndrome, and impaired consciousness [2].

66 Understanding the immune responses elicited by SARS-CoV-2 infection is critical in terms of
67 protection from re-infection and, thus, for public health policy and vaccine development. One of
68 the key roles of acquired immune responses is played by neutralizing antibodies (nAb) that are
69 generally associated with virus clearance and protection [3, 4]. Several reports indicate that most
70 of individuals recovering from SARS-CoV-2 infection develop IgM, IgG and IgA responses
71 targeting the nucleocapsid (N) or the spike (S) protein of the SARS-CoV-2 viral particles 7-14
72 days after infection [5-7]. Additionally, nAbs have been identified in patients, suggesting that
73 SARS-CoV-2 infection may generate a robust immune response [8, 9, 7]. Considering the lack of
74 perspectives on the immune correlates of protection against SARS-CoV-2, it is tempting to draw
75 conjecture from the immune responses elicited by other human coronaviruses. Hence, nAb
76 activity of sera from patients infected with endemic coronaviruses can rapidly wane over time,
77 as reinfection is frequently described [10], whereas nAbs against SARS-CoV and MERS-CoV

78 can be detected for up to 36 months [11, 12]. It is therefore urgent to evaluate the nAb response
79 elicited by SARS-CoV-2 infection, the factors associated with its robustness, and its persistence.
80 Here, the nAb activity of serum specimens from a cohort of 140 SARS-CoV-2 qPCR-confirmed
81 patients was quantified. We show that nAb titers are strongly correlated with disease severity.
82 Importantly, we were able to quantify the persistence of nAb activity in patients, which indicated
83 a relatively rapid decline of nAbs after recovery. We also showed the absence of cross-protection
84 conferred by previous infection by endemic coronaviruses. Finally, we found that the D614G
85 mutation in the Spike protein, that has recently been identified as the major variant now found in
86 Europe [13] did not induce nAb escape.

87

88 **Methods**

89 **Ethics.**

90 This study was approved by the Ethical Committee of the University Hospital of Saint-Etienne
91 (reference number IRBN512020/CHUSTE).

92

93 **Patients and origin of samples.**

94 A total of 140 patients followed at the University Hospital of Saint-Etienne were enrolled
95 between March and May 2020. All patients were sampled by nasal swab and tested positive for
96 SARS-CoV-2 RNA by RT-qPCR assay. The patients were classified in 3 groups according to
97 their medical care: 44 were admitted in intensive care unit (ICU), 42 were hospitalized (HOS)
98 without receiving care in ICU, and 54 were given exclusive outpatient care (EOC) including 8
99 asymptomatic cases (ASY).

100 In the ICU and HOS groups, 3-4 sera were sampled at three periods of follow-up after the onset
101 of symptoms: 0 to 15, 16 to 30 and > 30 days. In the EOC group, 2 sera were sampled from 13 to
102 62 days after the onset of symptoms.

103 Time post-onset was defined as the time after onset of the first symptoms.

104

105 **Seroneutralization assay using wild type SARS-CoV-2.**

106 The viral strain (RoBo strain) used this assay was a clinical isolate cultured on Vero-E6 cells
107 (kind gift from Pr. B. La Scola, IHU Méditerranée, Marseille, France) from a nasopharyngeal
108 aspirate of a patient hospitalized at the University Hospital of Saint-Etienne for severe COVID-
109 19 infection; it was diluted in DMEM containing 2% FCS so that to obtain 100 to 500 tissue
110 culture infectious doses 50% (TCID₅₀) per ml. Each serum specimen was diluted 1:10 and serial
111 two-fold dilutions were mixed with an equal volume (100 µl each) of the virus in a plastic
112 microplate. After gentle shaking and a contact of 30 minutes at room temperature, 150 µl of the
113 mixt was transferred to 96-well microplates covered with VeroE6 cells. The plates were then
114 placed at 37°C in a 5% CO₂ incubator. The reading was evaluated microscopically 5 to 6 days
115 later when the cytopathic effect of the virus control reached about 100 TCID₅₀/150 µl. The serum
116 was considered to having protected the cells if more than 50% of the cell layer was preserved.
117 The neutralizing titer was expressed as the inverse of the higher serum dilution that protected the
118 cells.

119

120 **SARS-CoV-2 pseudoparticles preparation and determination of neutralization.**

121 SARS-CoV-2 Spike-pseudotyped murine leukemia virus (MLV) retrovirus particles were
122 produced as described for SARS-CoV-1 [14]. Briefly, HEK293T cells (ATCC CRL-1573) were

123 transfected with constructs expressing MLV Gag-Pol, the green fluorescent protein (GFP)
124 reporter, and the SARS-CoV-2 Spike (kind gift from D. Lavillette). The plasmid encoding the
125 Spike protein harboring D614G mutation was generated by PCR mutagenesis. Control
126 pseudoparticles pseudotyped with the unrelated RD114 viral surface glycoprotein (from a cat
127 endogenous virus) were generated as previously described [15]. For neutralization assays, around
128 1×10^3 pseudoparticles were incubated with 100-fold dilution of sera or control antibodies 1h at
129 37°C prior to infection of VeroE6R (ATCC CRL-1586) cells. At 72h post transduction, the
130 percentage of GFP-positive cells was determined on by flow cytometry. As control the same
131 procedure was done using RD114 pseudoparticles.

132 Anti-Spike RBD SARS-CoV2 (Sino Biological) and anti-gp70 RD114 (79S914, ViroMed
133 Biosafety Labs) were used as positive and negative control neutralizing antibodies, respectively.

134

135 **Commercial kits for measuring IgG antibodies against SARS-CoV-2.**

136 Two commercially-available kits were used for measuring the anti-SARS-CoV-2 IgG antibodies.
137 The LIAISON® SARS-CoV-2 S1/S2 kit (Diasorin) measures antibodies against S1-S2 proteins
138 whereas the ARCHITECT SARS-CoV-2 IgG kit (Abbott Laboratories) measures antibodies to
139 the viral nucleoprotein.

140

141 **Statistical analysis.**

142 Analysis were performed using the GraphPad Prism 6 software. Significance values were
143 calculated by applying the Kruskal-Wallis test and Dunn's multiple comparison test or t-test
144 depending on the population and Spearman's coefficient and p-value were calculated to evaluate
145 the correlation between variables. Second order polynomial regression were plotted by line and

146 ribbons depicting the 95% confidence intervals. Parameters of the polynomial equations are
147 indicated on the graphs. P values under 0.05 were considered statistically significant and the
148 following denotations were used: ****, $P \leq 0.0001$; ***, $P \leq 0.001$; **, $P \leq 0.01$; *, $P \leq 0.05$; ns (not
149 significant), $P > 0.05$.

150

151 **Results**

152 **COVID-19 patients and clinical information.**

153 One hundred and forty (140) laboratory-confirmed SARS-CoV-2 consenting patients from the
154 University Hospital of Saint-Etienne (France) were enrolled in the study. Among them, 44
155 patients were admitted in intensive care unit (ICU), 42 patients were hospitalized (HOS) without
156 receiving care in ICU, and 54 patients were given exclusive outpatient care (EOC) including 8
157 patients who were asymptomatic (ASY). Finally, 9 serum specimens from subjects infected by
158 seasonal coronaviruses were also available for the study. 269 blood samples were collected from
159 the patients at various time points post-onset of COVID-19 symptoms, based on the availability
160 of discarded blood samples collected for routine clinical management. Importantly, several
161 patients were sampled at least three times: 19 ICU, 14 HOS and 4 EOC, to up to 63 days after
162 onset.

163 Overall, this cohort recapitulated the variability in the severity of COVID-19, and common
164 comorbidities already identified [16-18] were also present in this cohort. A full summary of the
165 characteristic of the patients is presented in Table 1. The main clinical symptoms in ICU and
166 HOS groups were fever (90.1%), dyspnea (56.3%), cough (53.5%), asthenia (29.6%), diarrhea
167 (23.9%), myalgia (8.5%), sputum production (7.0%) and anosmia/ageusia (4.2%). There were

168 no differences of clinical symptoms between these two groups, which differed essentially with
169 their severity. In the EOC group, moderate symptoms were mainly fever, cough and asthenia.

170

171 **Pseudoparticles neutralization is correlated with wild-type SARS-CoV-2 neutralization.**

172 Neutralization of live virus in *in vitro* assays is considered as the gold-standard method for the
173 assessment of nAbs. However, for SARS-CoV-2, it requires BSL-3 facility and it is time-
174 consuming. Hence, we developed a SARS-CoV-2 pseudoparticle assay, named SARS-CoV-2pp,
175 to quickly, safely and reliably assess nAb activity. This assay was compared to a classic
176 neutralization assay performed with wild-type SARS-CoV-2 in BSL-3 facility. To identify
177 unspecific neutralizing activity, each serum tested with SARS-CoV-2pp was tested in parallel
178 with RD114pp (Figure S1), *i.e.*, pseudoparticles coated with the glycoprotein gp70 of the
179 endogenous feline retrovirus RD114 [15].

180 We first compared the neutralizing activity of the sera or plasma from our cohort of COVID-19
181 patients using both live virus and pseudoparticle assays. For live virus, the neutralization was
182 assessed by ID50 (serum dilution that inhibits 50% of the infectivity) whereas for pseudoparticle
183 assays, it was expressed as % of neutralization at the serum dilution of 1/100, both relative to a
184 no serum condition. The nAb activity of each serum sample from the 140 patients as well as
185 negative sera, *i.e.* sera that were collected before the emergence of the outbreak and sera from
186 patients previously infected with other coronavirus (see below), were blindly quantified using
187 these two detection methods. Similar results were obtained (Figure 1A), as indicated by the high
188 Spearman's rank correlation ($\rho=0.75$). Hence, neutralization assays based on SARS-CoV-2
189 pseudoparticles can be reliably used to quantify nAb activity.

190

191 **SARS-CoV-2 nAb response is correlated with COVID-19 symptoms severity.**

192 To explore potential humoral protective immune responses generated after SARS-CoV-2
193 infection, we compared the nAb activity of serum samples from patients in function of the
194 severity of their symptoms. The nAb activity of their serum samples was evaluated using both
195 SARS-CoV-2pp and wild-type virus. The cut-off for neutralization, *i.e.*, 35%, was set using the
196 mean neutralization of a 1/100 dilution of the negative sera + 2 standard deviation [19] for
197 SARS-CoV-2pp. For wild-type virus, the cut-off for the ID50 was placed at the 1/10 dilution
198 (first tested dilution) as all negative sera were found below this threshold.

199 We found that most patients from the different groups developed nAbs, although the neutralizing
200 activity was highly variable (Figure 1C). Moreover, 44 patients (31.4%) exhibited a robust
201 neutralization allowing over 90% neutralization of SARS-CoV-2pp (Figure 1B, total).

202 Strikingly, we found that ICU patients were particularly prone to display high nAb activity as
203 compared to other groups with milder disease symptoms, such as HOS and EOC patients (Figure
204 1C). Indeed, only one patient in ICU did not develop a nAb response at the time of sampling,
205 whereas for the HOS and EOC patients, the nAb activity was lower and more heterogenous.
206 Specifically, 21.9% and 25% of patients in HOS and EOC categories respectively, did not
207 develop nAbs at the time of sampling (Figure 1C - right). In addition, 34.5% of HOS patients had
208 serum with no neutralizing activity at 1/100 and this number was increased to 70.7% in EOC
209 patients (Figure 1C - left).

210 Concerning the HOS patients, we sought to classify the patients according to the severity of their
211 symptoms. Accordingly, we defined as ‘severe’, the patients who had a respiratory rate >30/min
212 and/or blood oxygen saturation <92% and/or lung lesions observed by CT scan and/or intensive
213 oxygen therapy. The HOS patients were classified as ‘moderate’ if they did not fulfill the above

214 criteria. However, we did not find a significant correlation ($p=0.0981$) between the severity of
215 the symptoms of the HOS patients and their nAb titers, even though the % neutralization was
216 higher in serum of patients with more severe disease forms (Figure 1D). This indicated that the
217 severity of the symptoms may not be the only factor that explains the diversity of nAb activity in
218 the HOS patients. Additionally, we found that neither the age and gender criteria nor the Ct of
219 the first positive RT-qPCR titers (or the timing of sampling for qPCR) were associated with
220 stronger or weaker neutralization (Table S1). This excluded an impact of the viral load or a bias
221 due to the variability of the set-up of sampling in the heterogeneity of nAb activity observed in
222 these patients.

223 Overall, these results indicated that the nAb activity was highly correlated with the severity of
224 the symptoms, suggesting either that a robust humoral response was generated only in patients
225 with severe symptoms or that the humoral response may contribute to the aggravation of the
226 disease.

227

228 **SARS-CoV-2 anti-N and anti-S Abs correlate with neutralizing response.**

229 The high number of EOC patients without detectable nAb activity raises the question of the
230 identification of correlates of protection in infected patients, since high titers of nAbs are
231 generally thought to confer a protection against infection. Thus, we sought to identify whether
232 IgG responses raised against components of SARS-CoV-2 particles could be correlated with the
233 nAb activity detected in patients' samples. For this, the anti-S and anti-N IgG responses were
234 measured by two commercially-available tests. We found that most samples from SARS-CoV-2
235 positive patients were positive for at least one of either assay (Figure 2A, 2B). Interestingly,
236 while anti-S IgG titers were highly correlated with the nAb titers (Spearman's $\rho = 0.7075$, Fig

237 2B), the correlation was lower between anti-N IgG and nAbs (Spearman's $\rho = 0.5765$, Figure
238 2A). Such differences were particularly obvious when we compared the distribution of the IgG
239 among each category of patients. Indeed, while we found a low overlay in the profiles of anti-S
240 IgG between EOC and ICU patients, which appeared similar to those of nAbs (compare Figure
241 1C vs. Figure 2C left), we detected a strong overlay in the value of anti-N IgGs between EOC
242 and ICU patients (compare Figure 1C vs. Figure 2C right). This suggested that anti-S IgG values
243 are more relevant to mark the presence and levels of nAb activity. Indeed, our results indicate
244 that 95% of sera with above 124 AU/mL of anti-S IgGs were able to strongly neutralize SARS-
245 CoV-2pp (>90% neutralization).

246 Overall, these results indicated that the anti-S IgG response could be used as a surrogate of
247 neutralizing activity in individuals.

248

249 **SARS-CoV-2 Ab kinetics in patient indicate a rapid waning of nAb titers.**

250 Next, we evaluated the kinetics of the anti-S IgG and nAb activities in our cohort of COVID-19
251 patients. Indeed, beside the diversity of clinical forms, one key feature of our cohort is the serial
252 serum sampling for most patients, allowing to estimate the persistence of humoral factors. Both
253 anti-S IgGs and nAb activities were generally detectable at 5-7 days post-onset of symptoms in
254 patients who developed a humoral response, and rapidly increased to reach a peak before
255 declining (Figure 3A, 3B). Hence, the kinetics of nAb titers as well as of anti-S IgG in each
256 group were modeled with a second order polynomial (Figure 3A and 3B), which proved our
257 best model among different ones tested (see parameters indicated in Figure 3). This regression
258 analysis indicated that, instead of plateauing after the peak, the nAb activity could rapidly
259 decrease, with an estimated half-life of 26 days. Additionally, the general tendency for anti-S

260 IgGs seemed to follow the same pattern, with a peak and half-life similar to those calculated for
261 the nAb activity, further confirming the correlation between anti-S IgG and neutralizing activity.

262

263 **No cross-neutralization of SARS-CoV-2 can be induced by previous infection with**
264 **alternative coronaviruses.**

265 Previous reports suggested that immunity against other coronaviruses may confer a certain
266 degree of protection against alternative coronaviruses [20]. Hence, we explored the possibility
267 that serum specimens from individuals diagnosed for OC43, 229E, NL63 and HKU1
268 coronaviruses (Figure 4A) but not infected with SARS-CoV-2 could cross-neutralize SARS-
269 CoV-2. However, we found that none of the tested samples showed neutralizing activity above
270 the cut-off of detection (Figure 4B), suggesting the absence of cross-neutralization between
271 SARS-CoV-2 and endemic coronaviruses.

272

273 **D614G substitution is not associated with resistance to SARS-CoV-2 neutralization.**

274 Considering the level of occurring mutations in coronaviruses, concerns have been raised about
275 the emergence of SARS-CoV-2 immune escape mutants. In particular, the G614 variant in the
276 Spike protein has progressively emerged and replaced the D614 initially present in the Wuhan
277 strain to become the dominant pandemic form, which currently constitutes >97% of isolates
278 world-wide [13]. To address the possibility of a neutralization escape phenotype potentially
279 conferred by the D614G mutation, we used the SARS-CoV-2pp assay, which is particularly
280 suitable to compare the nAb activity of serum specimens against pseudoparticles harboring or
281 not this mutation. Yet, we found that that D614G mutation did not affect nAb activity of the
282 serum samples from our cohort, as shown by similar profiles of neutralization (Figure 5),

283 indicating that this highly prevalent mutation does not play a role in SARS-CoV-2 immune
284 escape but rather may modulate viral fitness and infection [21].

285

286 **Discussion**

287 Our understanding of the nature of protective immune response to SARS-CoV-2 is currently
288 limited but is likely to involve both cellular and humoral immunity. Here, we characterize some
289 features of the humoral response in a cohort of individuals infected with SARS-CoV-2. The
290 serum specimens used in this study were collected according to the routinely clinical
291 management, without selection of specific criteria. Although this may limit its statistical
292 interpretation, this cohort represents a particularly appropriate picture of the different forms of
293 severity for COVID-19 patients and, thus, allows an original longitudinal study.

294

295 Using either a live virus or a pseudotyped system, we compared the nAb response in sera from
296 patients with different levels of COVID-19 severity, according to their hospitalization status,
297 including patients in intensive care unit but also SARS-CoV-2-positive individuals with more
298 moderate disease forms. Recent reports have evaluated the neutralizing activity of sera from
299 COVID-19 patients with controversial results. While a study suggested that patients rapidly
300 develop neutralizing antibodies [22], other studies indicated that the humoral response [23] and
301 nAb activity [24, 23] are correlated to several parameters including the severity of the disease,
302 resulting in the absence of detection of nAb activity in a significant number of mild symptomatic
303 and asymptomatic patients [25]. However, such assumptions were based on a very limited
304 number of observations, since those studies included less than 10 patients with the most severe
305 forms. Our cohort is composed of 140 patients, one third of whom are ICU patients, which

306 represent the largest clinical cohort published to date in which neutralizing activity has been
307 evaluated. Those characteristics allowed us to address important questions such as correlations of
308 nAb activity with disease severity, IgG response, or kinetics of antibody levels. Here, we
309 confirmed the heterogeneity of the humoral response in COVID-19 patients. While we found that
310 parameters, such as age or gender, were not associated with nAb activity, we show that among
311 patients with mildest disease forms, many did not exhibit robust neutralizing activities (Figure
312 1). Importantly, we demonstrated that the severity of the disease, as assessed by the
313 hospitalization unit status, strongly correlated with the levels of nAbs as well as with anti-S IgG
314 titers (Figure 1 and Figure 2). This ties with a recent observation that the strongest T cell signals
315 are found in patients with the most severe disease forms, raising the question of the beneficial vs.
316 detrimental effect of T cell activation in SARS-CoV-2 pathogenesis [26].

317
318 Importantly, while for most viral infections, high neutralizing antibody titers are usually
319 associated with viral clearance, it seems that a robust nAb activity does not confer protection
320 against disease progression in COVID-19 patients. One possibility is that disease severity is
321 correlated with higher viral loads and hence, with more antigens available for induction of
322 antibodies. Yet, no correlation between viral loads and nAb activity could be identified in our
323 cohort (Table S1), though the assessment of the viral loads by the first positive qPCR could be
324 unreliable, due to parameters that can influence the quality of sampling [27]. Alternatively, a
325 robust humoral response may be a feature of an overall exaggerated immune activation in severe
326 SARS-CoV-2 infection. Indeed, antibodies could mediate additional immune functions that may
327 have both protective and pathological consequences. In addition, humoral responses have been
328 shown to be correlated with cytokines and chemokines levels in COVID-19 patients [28] that are

329 the main effectors of severe systemic inflammatory responses known as “cytokine storm” found
330 in the most severe forms of the disease [29]. Thus, an uncontrolled humoral response may also
331 contribute directly to the pathogenesis of the disease by promoting organ damages, but this
332 mechanism has to be demonstrated for SARS-CoV-2. In this perspective, questions about the use
333 of convalescent plasma transfusion as a treatment for COVID-19 could be raised, since it is
334 uncertain whether such transfusion may lead to an aggravation of the disease [30].

335
336 The correlation between seroconversion and nAb activity was also analyzed (Figure 2 and Figure
337 3). As expected, both anti-S and anti-N IgG levels correlated with nAb titers, although
338 correlation with anti-S antibodies was the strongest, which likely reflects Spike being the main
339 target of nAbs for diverse coronaviruses, including SARS-CoV-2 [31]. Thus, should neutralizing
340 activity be associated with protection against subsequent re-infections, the determination of anti-
341 S IgG titers, by *e.g.*, ELISA, may be useful to discriminate protected from unprotected
342 individuals, in particular for patients with the most moderate forms, since they are less prone to
343 develop robust neutralizing activity. In our cohort, 95% of sera with anti-S antibody values
344 above 124 AU/mL were associated with robust neutralization (90% neutralization or more),
345 suggesting that anti-S antibody determination could be used as an evaluation of nAb activity,
346 rather than for anti-N IgG assays.

347
348 We also addressed the question of the stability of the nAb levels, owing to the availability of
349 several serial samples for most of the patients used in the study. We confirmed a tendency for a
350 decrease of the nAb activity as well as of anti-S IgG after reaching a peak, as previously shown
351 by others [32], indicating that for some patients, the nAb activity may be very transient (Figure

352 3). Importantly, for ICU patients, we were able to give a more precise estimation of the
353 persistence of the neutralizing activity, with a preliminary estimation of 26 days for its half-life.
354 Thus, our model predicts that the SARS-CoV-2 nAb activity is likely to rapidly vanish. These
355 results, which need to be confirmed by studying alternative COVID-19 cohorts and more
356 patients, are in sharp contrast with SARS-CoV-induced disease, for which the nAbs could be
357 detected for about 270 days with ID₅₀>100 [33]. Thus, for SARS-CoV-2, it remains to be
358 determined if such waning of the nAb activity is associated with an absence of protection or,
359 alternatively, if potential re-infections may trigger immune memory and induce faster and higher
360 production of nAbs, eventually leading to a better control of the infection and/or to reduced
361 symptoms. Further studies are warranted for the evaluation of the persistence of SARS-CoV-2
362 nAbs.

363
364 Naturally occurring variants in S proteins have been reported since the beginning of the
365 pandemic. Among them, a variant with a single mutation in 614 position (D614G) has become
366 the currently dominant circulating virus. This variant has been associated with increased
367 infectivity though it did not exhibit resistance to nAb present in convalescent sera [21]. Our
368 report confirms that, by comparing the neutralizing activity for SARS-CoV-2pp with a D614 and
369 G614 S, this mutation is not associated with resistance to neutralization.

370
371 Finally, we also analyzed 9 serum samples from patients infected with alternative coronaviruses
372 that cause mild symptom in adults, including respiratory illnesses, and enteric and neurological
373 diseases [34]. The cross reactivity between other coronaviruses and SARS-CoV-2 immunity is
374 key to understand, as it might influence the severity of the disease or the response to a vaccine

375 [35]. In line with this, T cell reactivity against SARS-CoV-2 was observed in unexposed people
376 [36]. Interestingly, by investigating the cross reactivity of circulating Abs, we found that none of
377 the 9 samples displayed cross-reacting nAbs against SARS-CoV-2 infection. Furthermore, cross-
378 neutralization against SARS-CoV-2 can be induced by sera from convalescent SARS-CoV
379 patients, which is likely due to high homology between these two viruses, although it seems to be
380 serum-dependent [37, 38]. Thus, our results indicate an absence of cross-neutralization between
381 SARS-CoV-2 and other endemic human coronaviruses, suggesting that previous infections with
382 alternative coronaviruses do not protect against SARS-CoV-2 infection by generation of nAbs.

383

384 **Acknowledgments**

385 We thank D. Lavillette for providing the SARS-CoV-2 Spike expression vector and B. La Scola
386 for providing a clone of VERO-E6 cells.

387 We acknowledge the contribution of SFR Biosciences (UMS3444/CNRS, US8/Inserm, ENS de
388 Lyon, UCBL) ANIRA-Cytometry facility for excellent technical assistance and support.

389 The laboratory of FLC received financial support from the LabEx Ecofect (ANR-11-LABX-
390 0048) of the “Université de Lyon”, within the program “Investissements d’Avenir” (ANR-11-
391 IDEX-0007) operated by the French National Research Agency (ANR), the ANR (grant from
392 RA-Covid-19), the Fondation pour la Recherche Médicale (FRM), and Inserm Transfert.

393

394 **Authorship Contributions**

395 Study concept and design: BB, MV, TB, FLC, SD, VL, BP. Inclusion and characterization of
396 patients: PB, EBN, TG, CP, MV, TB. Acquisition of data: BB, SD, VL, SP, SG, JR, PV, BP.

397 Analysis and interpretation of data: OA, FG, BB, SP, TB, FLC, SD, VL, BP. Drafting of the
398 manuscript: BB TB, FLC, SD, VL, BP. Funding acquisition: BB, TB, FLC, SD, VL, TW.

399

400 **Disclosure of Conflicts of Interest**

401 The authors have declared that no competing interests exist.

402

403 **References**

404 1. Pascarella G, Strumia A, Piliiego C, Bruno F, Del Buono R, Costa F et al. COVID-19
405 diagnosis and management: a comprehensive review. *J Intern Med.* 2020;288(2):192-206.
406 doi:10.1111/joim.13091.

407 2. Acharya A, Kevadiya BD, Gendelman HE, Byrareddy SN. SARS-CoV-2 Infection Leads to
408 Neurological Dysfunction. *J Neuroimmune Pharmacol.* 2020;15(2):167-73. doi:10.1007/s11481-
409 020-09924-9.

410 3. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y et al. Serology for SARS-
411 CoV-2: Apprehensions, opportunities, and the path forward. *Sci Immunol.* 2020;5(47).
412 doi:10.1126/sciimmunol.abc6347.

413 4. Suthar MS, Zimmerman M, Kauffman R, Mantus G, Linderman S, Vanderheiden A et al.
414 Rapid generation of neutralizing antibody responses in COVID-19 patients. *medRxiv.* 2020.
415 doi:10.1101/2020.05.03.20084442.

416 5. Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J et al. Antibody Detection and Dynamic
417 Characteristics in Patients with COVID-19. *Clin Infect Dis.* 2020. doi:10.1093/cid/ciaa461.

- 418 6. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F et al. Profiling Early Humoral Response to
419 Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis.* 2020;71(15):778-85.
420 doi:10.1093/cid/ciaa310.
- 421 7. Zhao R, Li M, Song H, Chen J, Ren W, Feng Y et al. Early detection of SARS-CoV-2
422 antibodies in COVID-19 patients as a serologic marker of infection. *Clin Infect Dis.* 2020.
423 doi:10.1093/cid/ciaa523.
- 424 8. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S et al. Neutralizing antibody responses to
425 SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *medRxiv.*
426 2020:2020.03.30.20047365. doi:10.1101/2020.03.30.20047365.
- 427 9. Long Q-x, Deng H-j, Chen J, Hu J, Liu B-z, Liao P et al. Antibody responses to SARS-CoV-2
428 in COVID-19 patients: the perspective application of serological tests in clinical practice.
429 *medRxiv.* 2020:2020.03.18.20038018. doi:10.1101/2020.03.18.20038018.
- 430 10. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to
431 experimental coronavirus infection of man. *Epidemiol Infect.* 1990;105(2):435-46.
432 doi:10.1017/s0950268800048019.
- 433 11. Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, Al Nsour M et al. Persistence of
434 Antibodies against Middle East Respiratory Syndrome Coronavirus. *Emerg Infect Dis.*
435 2016;22(10):1824-6. doi:10.3201/eid2210.160706.
- 436 12. Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-
437 associated coronavirus after recovery. *N Engl J Med.* 2007;357(11):1162-3.
438 doi:10.1056/NEJMc070348.

- 439 13. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W et al. Tracking
440 Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19
441 Virus. *Cell*. 2020. doi:10.1016/j.cell.2020.06.043.
- 442 14. Broer R, Boson B, Spaan W, Cosset FL, Corver J. Important role for the transmembrane
443 domain of severe acute respiratory syndrome coronavirus spike protein during entry. *J Virol*.
444 2006;80(3):1302-10. doi:10.1128/JVI.80.3.1302-1310.2006.
- 445 15. Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E et al. Human serum
446 facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral
447 replication kinetics at the acute phase of hepatitis C virus infection. *J Virol*. 2005;79(10):6023-
448 34. doi:10.1128/JVI.79.10.6023-6034.2005.
- 449 16. Siordia JA, Jr. Epidemiology and clinical features of COVID-19: A review of current
450 literature. *J Clin Virol*. 2020;127:104357. doi:10.1016/j.jcv.2020.104357.
- 451 17. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V et al. Clinical Features of
452 COVID-19 and Factors Associated with Severe Clinical Course: A Systematic Review and
453 Meta-Analysis. *SSRN*. 2020:3566166. doi:10.2139/ssrn.3566166.
- 454 18. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM et al. Comorbidity and its impact
455 on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J*. 2020;55(5).
456 doi:10.1183/13993003.00547-2020.
- 457 19. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M et al. A
458 serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*. 2020;26(7):1033-
459 6. doi:10.1038/s41591-020-0913-5.
- 460 20. Tong PB, Lin LY, Tran TH. Coronaviruses pandemics: Can neutralizing antibodies help?
461 *Life Sci*. 2020;255:117836. doi:10.1016/j.lfs.2020.117836.

- 462 21. Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S et al. The Impact of Mutations in SARS-CoV-2
463 Spike on Viral Infectivity and Antigenicity. *Cell*. 2020. doi:10.1016/j.cell.2020.07.012.
- 464 22. Fafi-Kremer S, Bruel T, Madec Y, Grant R, Tondeur L, Grzelak L et al. Serologic responses
465 to SARS-CoV-2 infection among hospital staff with mild disease in eastern France.
466 *EBioMedicine*. 2020:102915. doi:10.1016/j.ebiom.2020.102915.
- 467 23. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y et al. Antibody responses to SARS-CoV-2 in
468 patients of novel coronavirus disease 2019. *Clin Infect Dis*. 2020. doi:10.1093/cid/ciaa344.
- 469 24. Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J et al. Neutralizing Antibodies Responses to
470 SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. *Clin Infect Dis*. 2020.
471 doi:10.1093/cid/ciaa721.
- 472 25. Ko JH, Joo EJ, Park SJ, Baek JY, Kim WD, Jee J et al. Neutralizing Antibody Production in
473 Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19
474 Patients. *J Clin Med*. 2020;9(7). doi:10.3390/jcm9072268.
- 475 26. Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability,
476 and role in protection. *Sci Immunol*. 2020;5(49). doi:10.1126/sciimmunol.abd6160.
- 477 27. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in
478 the laboratory diagnosis of coronavirus disease 2019 (COVID-19). *Clin Chem Lab Med*.
479 2020;58(7):1070-6. doi:10.1515/cclm-2020-0285.
- 480 28. Wang K, Long QX, Deng HJ, Hu J, Gao QZ, Zhang GJ et al. Longitudinal dynamics of the
481 neutralizing antibody response to SARS-CoV-2 infection. *Clin Infect Dis*. 2020.
482 doi:10.1093/cid/ciaa1143.

- 483 29. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W et al. Profiling serum cytokines in COVID-19
484 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg Microbes Infect.*
485 2020;9(1):1123-30. doi:10.1080/22221751.2020.1770129.
- 486 30. Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM et al. Convalescent plasma or
487 hyperimmune immunoglobulin for people with COVID-19: a living systematic review. *Cochrane*
488 *Database Syst Rev.* 2020;7:CD013600. doi:10.1002/14651858.CD013600.pub2.
- 489 31. Tortorici MA, Veessler D. Structural insights into coronavirus entry. *Adv Virus Res.*
490 2019;105:93-116. doi:10.1016/bs.aivir.2019.08.002.
- 491 32. Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O et al. Longitudinal
492 evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv.
493 2020:2020.07.09.20148429. doi:10.1101/2020.07.09.20148429.
- 494 33. Mo H, Zeng G, Ren X, Li H, Ke C, Tan Y et al. Longitudinal profile of antibodies against
495 SARS-coronavirus in SARS patients and their clinical significance. *Respirology.* 2006;11(1):49-
496 53. doi:10.1111/j.1440-1843.2006.00783.x.
- 497 34. Liu DX, Liang JQ, Fung TS. Human Coronavirus-229E, -OC43, -NL63, and -HKU1.
498 Reference Module in Life Sciences. Elsevier; 2020.
- 499 35. Sette A, Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. *Nat*
500 *Rev Immunol.* 2020;20(8):457-8. doi:10.1038/s41577-020-0389-z.
- 501 36. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR et al. Targets of T
502 Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
503 Unexposed Individuals. *Cell.* 2020;181(7):1489-501 e15. doi:10.1016/j.cell.2020.05.015.

- 504 37. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S et al. SARS-
505 CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
506 Protease Inhibitor. *Cell*. 2020. doi:10.1016/j.cell.2020.02.052.
- 507 38. Yang R, Lan J, Huang B, A R, Lu M, Wang W et al. Lack of antibody-mediated cross-
508 protection between SARS-CoV-2 and SARS-CoV infections. *EBioMedicine*. 2020;58:102890.
509 doi:10.1016/j.ebiom.2020.102890.

510 **Table 1. Characteristics of the three groups of COVID-19 patients.**
511

Characteristics	Patient's group		
	Intensive care ICU (n=44)	Hospitalized HOS (n=42)	Ambulatory EOC + ASY (n=54)
M/F sex ratio	0.6	1.6	3.9
Age (years), median (IQR)	70 (64-75.8)	82 (65-85.2)	37 (32-50.5)
Comorbidities (%)			
Age >70	52.3	69.0	7.4
Obesity	25.0	9.7	0
Hypertension	62.5	61.3	0
Diabetes	30.0	22.6	0
Cardiovascular disease	12.5	41.9	0
Kidney failure	12.5	6.4	0
Chronic respiratory diseases	17.5	16.1	0
Malignancy	5	19.4	0
Severity criteria (%)			
Respiratory rate >30/min	70	6.5	0
Blood oxygen saturation <92%	97.5	22.6	0
Severe injuries by CT scan	92.5	38.7	0
Oxygen and/or mechanical ventilation needs	100	45.1	0
Deceased (%)	16.3	15.4	0

512 **Figure legends**

513

514 **Figure 1. Serum neutralization of SARS-CoV-2 is correlated with the units of**
515 **hospitalization of COVID-19 patients.**

516 (A) Correlation between ID50 of live virus, plotted as number of dilutions (two-fold dilutions,
517 starting from serum diluted at 1/10), with percentage of neutralization of SARS-CoV-2pp for all
518 tested samples. (B) Number of patients classified in the indicated groups according to the
519 percentage of neutralization. In white: samples that induced a percentage of neutralization below
520 90%. (C) Comparison of the percentage of neutralization with SARS-CoV-2pp (left) or ID50
521 with live virus (right) for each patient classified according to the unit of hospitalization. For
522 patients with serial serum samples, the sera collected at the closest to twenty days post-onset of
523 symptoms were chosen. In light green are represented the asymptomatic patients (ASY) among
524 the EOC patients. (D) Percentage of neutralization according to severity of symptoms in HOS
525 patients.

526

527 **Figure 2. Serum neutralization of SARS-CoV-2 is correlated to anti-S antibodies.**

528 (A) Correlation between the % of neutralization of SARS-CoV-2pp (left) or ID50 of live virus
529 (right) with seroconversion measured by anti-N antibodies. (B) Same as (A) with anti-S
530 antibodies. (C) Anti-S (left) and anti-N (right) IgG values distribution in the three groups of
531 patients.

532

533 **Figure 3. Apparition and longevity of neutralizing antibodies.**

534 (A) Seroconversion assessed by anti-S IgGs plotted against the days post-symptoms at which
535 samples were collected. (B) Percentage of neutralization of each serum assessed with SARS-
536 CoV-2pp plotted against the days post-symptoms at which samples were collected. The lines
537 show the mean values expected from a second order polynomial regression, the ribbons indicate
538 the pointwise 95% confidence intervals. The parameters of the regression analysis are indicated
539 to the right.

540

541 **Figure 4. Sera from patients infected by endemic coronaviruses have no cross-neutralizing**
542 **activity against SARS-CoV-2.**

543 (A) Characteristics of samples from patients infected with other coronaviruses. (B)
544 Seroconversion assessed by anti-N (left), anti-S (middle) of SARS-CoV-2 or neutralization
545 measured by SARS-CoV-2pp (right). For neutralization assays, a commercial anti-S antibody
546 was used as positive control (control +) and five pre-pandemic serum samples were used as a
547 negative control (control -).

548

549 **Figure 5: Residue at position 614 of SARS-CoV-2 Spike does not influence the activity of**
550 **nAb.**

551 Percentage of neutralization of SARS-CoV-2pp using Spike protein with either a G or D at
552 position 614.

553

554

555

556

557

558 **Supplementary Material**

559

560 **Figure S1 legend. Neutralizing antibodies are specific to SARS-CoV-2.**

561 Results of neutralization using control of pseudoparticles generated with the RD114 cat
562 endogenous virus surface glycoprotein.

563

564 **Table S1. Absence of correlation between age or the gender criteria or Ct of first PCR or**
565 **timing of sampling with neutralization.**

Criteria	P-value
ICU	
Age	0.694
Gender	0.367
Ct 1 st PCR	0.843
Timing of sampling	0.216
HOS	
Age	0.086
Gender	0.44
Ct 1 st PCR	0.8
Timing of sampling	0.97
EOC	
Age	0.92
Gender	0.51
Ct 1 st PCR	0.14
Timing of sampling	0.65

566





Figure 1

Pseudoparticles

Live virus



• ICU • HOS • EOC • Other coronavirus






Figure 2



$y = ax^2+bx+c$

		value	SD	P value
a	ICU	-0.02160	0.04482	****
	HOS	-0.1154	0.03306	***
	EOC	-0.03019	0.02143	ns
b	ICU	16.37	24.08	****
	HOS	7.442	1.958	***
	EOC	2.152	1.469	ns
c	ICU	-72.32	38.74	ns
	HOS	-11.09	24.08	ns
	EOC	2.515	23.18	ns



$y = ax^2+bx+c$

		value	SD	P value
a	ICU	-0.07214	0.01224	****
	HOS	-0.05660	0.01715	**
	EOC	0.00489	0.01611	ns
b	ICU	5.028	0.7728	****
	HOS	3.693	1.016	***
	EOC	-0.5820	1.080	ns
c	ICU	9.342	10.34	ns
	HOS	-5.22	12.25	ns
	EOC	33.48	16.73	*

Figure 3

A

	Number of patients	Age (year)	Gender (N male, %)
CoV-OC43	2	(61-67)	1 (50%)
CoV-229E	3	(68-73)	2 (33.3%)
CoV-NL63	3	(18-73)	1 (66.7%)
CoV-HKU1	1	2	1 (100%)

B




Figure 4




Figure 5